Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05578703 · ClinicalTrials.gov registry record · NA

ABLATE WEIGHT (Ablation Plus ESG for Weight Loss)

A NA study of Obesity, sponsored by True You Weight Loss.

Active
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT05578703: Active NA study of Obesity, sponsored by True You Weight Loss.

NCT05578703 is a NA study of Obesity that is active but no longer recruiting, run by True You Weight Loss. The registered enrollment target is 10 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05578703, a NA study of Obesity, is active but no longer recruiting, sponsored by True You Weight Loss.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research is to investigate the effects of fundic ablation (FA) on circulating plasma ghrelin, satiation, and total body weight loss, as well as the incidence of adverse events. This procedure will be carried out with the HybridAPC (ERBE Elektromedizin GmbH, Tübingen, Germany). The HybridAPC instrument creates an electric current to deliver a safe amount of thermal injury to a portion of the stomach known as the gastric fundus. This thermal injury will target a hormone called ghrelin which is the only known hormone linked to increasing appetite, calorie intake, and weight gain. This procedure is designed to target the bodily effects of appetite control and gastric sensory and motor functions which cause the feeling of fullness and satiation. The fundic mucosal ablation is not typically done prior to the endoscopic sleeve gastroplasty procedure. When fundic mucosal ablation is sequentially paired with endoscopic sleeve gastroplasty (ESG), this combined investigational approach may lead to decreased fasting ghrelin levels, improved satiation, and greater total body weight loss than traditional ESG. This study will help determine if the combined impact of FA with ESG should be made available to patients as part of a comprehensive weight loss strategy.

Conditions Studied

Obesity

Interventions

  • PROCEDURE Fundic Ablation Sequentially in Combination with Endoscopic Sleeve Gastroplasty
  • DEVICE Fundic Mucosal Ablation with ERBE HybridAPC
  • DEVICE Apollo ESG

Study Locations (1)

North Carolina

  • True You Weight Loss - Cary

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2022-11-09
Est. Completion 2026-06
Phase NA

Sponsor

True You Weight Loss

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05578703

The ClinicalTrials.gov registry entry for NCT05578703 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (99% lower). The listed sponsor is True You Weight Loss, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which Fundic Ablation Sequentially in Combination with Endoscopic Sleeve Gastroplasty is the first listed.

NCT05578703 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT05578703 about?

NCT05578703 is a clinical study titled "ABLATE WEIGHT (Ablation Plus ESG for Weight Loss)". The purpose of this research is to investigate the effects of fundic ablation (FA) on circulating plasma ghrelin, satiation, and total body weight loss, as well as the incidence of adverse events. This procedure will be carried out with the HybridAPC (ERBE Elektromedizin GmbH, Tübingen, Germany). Th...

What is the current status of trial NCT05578703?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2022-11-09. Estimated completion is 2026-06.

What conditions does trial NCT05578703 study?

This clinical trial studies the following conditions: Obesity.

What interventions are being tested in trial NCT05578703?

The interventions under investigation include: Fundic Ablation Sequentially in Combination with Endoscopic Sleeve Gastroplasty (PROCEDURE), Fundic Mucosal Ablation with ERBE HybridAPC (DEVICE), Apollo ESG (DEVICE).

Who is sponsoring clinical trial NCT05578703?

This trial is sponsored by True You Weight Loss, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05578703 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.